Literature DB >> 12815651

Models of Parkinson's disease.

Michael Orth1, Sarah J Tabrizi.   

Abstract

Parkinson's disease (PD) is a heterogenous disease likely to be caused by more than one specific aetiological factor. In rare familial cases of PD with similar clinical features to the idiopathic form of the disease, the underlying genetic cause has been identified. These PD-associated genes have been manipulated to create animal and cell culture models of the disease that have helped to further our understanding of the pathogenesis of PD, particularly concerning causes of the selective loss of dopaminergic neurons at the molecular level. In addition, these models will aid the future development of rational therapeutic strategies. This study briefly reviews toxin-induced models and the genetics of PD. It focuses on recently developed animal models of PD, as well as in vitro approaches to model the disease. Copyright 2003 Movement Disorder Society

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12815651     DOI: 10.1002/mds.10447

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  17 in total

Review 1.  Herpes simplex virus-based vectors.

Authors:  Robin Lachmann
Journal:  Int J Exp Pathol       Date:  2004-10       Impact factor: 1.925

2.  The effects of age and lipopolysaccharide (LPS)-mediated peripheral inflammation on numbers of central catecholaminergic neurons.

Authors:  P R Mouton; B Kelley-Bell; D Tweedie; E L Spangler; E Perez; O D Carlson; R G Short; R deCabo; J Chang; D K Ingram; Y Li; N H Greig
Journal:  Neurobiol Aging       Date:  2010-11-19       Impact factor: 4.673

Review 3.  Serotonergic mechanisms in Parkinson's disease: opposing results from preclinical and clinical data.

Authors:  B Scholtissen; F R J Verhey; H W M Steinbusch; A F G Leentjens
Journal:  J Neural Transm (Vienna)       Date:  2005-10-27       Impact factor: 3.575

4.  Fluoxetine improves the effect of levodopa on 6-hydroxy dopamine-induced motor impairments in rats.

Authors:  Javad Mahmoudi; Alireza Mohajjel Nayebi; Siyamak Reyhani-Rad; Morteza Samini
Journal:  Adv Pharm Bull       Date:  2012-06-15

5.  Dopaminergic neurotoxicant 6-OHDA induces oxidative damage through proteolytic activation of PKCδ in cell culture and animal models of Parkinson's disease.

Authors:  Calivarathan Latchoumycandane; Vellareddy Anantharam; Huajun Jin; Anumantha Kanthasamy; Arthi Kanthasamy
Journal:  Toxicol Appl Pharmacol       Date:  2011-08-06       Impact factor: 4.219

Review 6.  Neurodegeneration and cell replacement.

Authors:  Brandi K Ormerod; Theo D Palmer; Maeve A Caldwell
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2008-01-12       Impact factor: 6.237

Review 7.  Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials.

Authors:  Jaime Kulisevsky; Javier Pagonabarraga
Journal:  Drug Saf       Date:  2010-02-01       Impact factor: 5.606

Review 8.  Glutamate receptors as therapeutic targets for Parkinson's disease.

Authors:  Kari A Johnson; P Jeffrey Conn; Colleen M Niswender
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-12       Impact factor: 4.388

Review 9.  CD200-CD200R regulation of microglia activation in the pathogenesis of Parkinson's disease.

Authors:  Xi-Jin Wang; Min Ye; Yu-Hong Zhang; Sheng-Di Chen
Journal:  J Neuroimmune Pharmacol       Date:  2007-05-18       Impact factor: 4.147

10.  Involvment of cytosolic and mitochondrial GSK-3beta in mitochondrial dysfunction and neuronal cell death of MPTP/MPP-treated neurons.

Authors:  Agnès Petit-Paitel; Frédéric Brau; Julie Cazareth; Joëlle Chabry
Journal:  PLoS One       Date:  2009-05-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.